Floatz logo

Semaglutide

Chronic Heart Failure

University Medical Centre Ljubljanaprotein_peptidePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Chronic Heart Failure cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jacob Moller
Phase 4BB
Finerenone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Rivaroxaban
Janssen Research & Development, LLC
Phase 3B
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4B

View all 40 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →